← Russell 3000 cross-section

DCTH DELCATH SYSTEMS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$567m
Revenue TTM
$95m
Net income TTM
$0m
Free cash flow
$18m
Composite score
67.2
Sector rank
#2349

Valuation

P / E
1,065.1
EV / EBITDA
EV / sales
4.9
FCF yield
3.09%
Earnings yield vs 10-yr
-4.64pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
0.6%
EBITDA margin
-1.5%
ROE
0.4%
ROIC
-7.2%
Revenue growth
35.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Results of Operations Revenue The increase in total revenue for the three and six months ended June 30, 2026 compared to the same period in 2025 was due to the continued commercial expansion and demand of HEPZATO in the United States. For the six months ended June 30, 2026, two customers each accounted for more than 10% of our total product revenue, representing in the aggregate approximately 29.2% of revenue. As of June 30, 2026, our largest customer by revenue accounted for approximately 19.0% of our total accounts receivable balance of $15.9 million. …DELCATH SYSTEMS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →